Moreover, BC patients with overexpression of CXCL9 presenting a PR-negative subgroup may have a longer RFS (Figure 4G, PR-, HR=0.57, P<0.01; Figure 4H, PR+, HR=1.27, P=0.17), while no significant difference was found in BC patients in the PR-positive subgroup. This evidence concerns the gene CXCL9 and breast cancer.